

# EVALUATION OF INVITRO ANTI-DIABETIC POTENTIALS OF BIOSYNTHESED MgO NANOPARTICLES FROM *Vernonia amygdalina* (BITTER LEAF) AQUEOUS LEAF EXTRACT

## ABSTRACT

**Introduction:** *Vernonia amygdalina* is a common shrub that is widely used and extracts from them have been traditionally used as remedies for treating diabetes mellitus in various parts of the world. The use of *V. amygdalina* to synthesize MgO nanoparticles has been used for various biomedical applications and it is compatible with anti-diabetic studies. This research investigates the invitro anti-diabetic potentials of MgONPs biosynthesized from aqueous *V. amygdalina* leaf extract.

**Methodology:** Aqueous extract of *V. amygdalina*-MgO nanoparticles was characterized using FTIR, XRD and SEM techniques. FTIR validated the presence of functional groups, the crystallization and size (66nm) of the nanoparticles was validated by XRD while SEM confirmed the shape of the nanoparticles synthesized.

**Result:** The phytochemical screenings of the crude and MgONPs- *V. amygdalina* extract were also carried out and qualitative screening confirmed the presence of saponin, flavonoids, phenols, alkaloids, tannins, terpenoids, glycosides while their concentrations were evaluated quantitatively. MgONPs-*V. amygdalina* extract's anti-diabetic potentials were evaluated via  $\alpha$ -amylase and  $\alpha$ -glucosidase inhibition analysis with acarbose as the standard drug in the lab. *V. Amygdalina*-MgONPs extract and acarbose showed significant inhibition of  $\alpha$ -amylase and  $\alpha$ -glucosidase, with IC<sub>50</sub> values of 55.05% and 20.0% respectively.

**Conclusion:** The study found that biosynthesized MgONPs-*V. amygdalina* aqueous extract has strong anti-diabetic properties, indicating its potential for diabetes treatment and management.

**Keywords:** *Vernonia amygdalina*, Antidiabetic activity, MgO nanoparticles.

## INTRODUCTION

Diabetes mellitus is a widespread, chronic metabolic disorder symbolized by high glucose level in the blood, posing significant global health risks. The therapy of diabetes aims to maintain normal blood glucose levels after meals for diabetic patients, particularly Type 2.(1).

Traditional healers in Africa use various plants to treat diabetes mellitus(2). Plant-based bitter principles have been linked to improved symptoms of diabetes mellitus(3). *V. amygdalina*, a medium-sized shrub with abundant bitter principles, is extensively harnessed in Nigeria for therapeutic and nutritive goals due to its therapeutic potentials. Extracts of this plant have been traditionally harnessed as traditional remedies for treating diabetes mellitus globally(4). (5) reported *V. amygdalina* is also used widely in Africa for conventional therapy of ailments like gastrointestinal issues, malaria, sexually transmitted diseases and infertility. Conventional utility of this plant extends beyond humans, as they are also used in the production of horse feed which provides chusandokin (a strengthening or fattening tonic) in the Northern part of Nigeria(6).

Nanoparticles are rapidly known for their relevance in ecological remedy, medicine, consumer goods, and other fields(7). NPs' unique properties have been harnessed in various areas such as healthcare, beauty products, renewable energy, ecological remedy and biomedical applications(8). (9) reported that MgNPs are highly popular due to their broad spectrum of bactericidal and fungicidal activity across various scientific applications. Green-based MgONPs synthesis involving bacteria, algae, fungi, and plants has gained popularity in medicine due to its eco-friendliness, low cost, toxicity, and long-lasting stability(10). Generally, plants' phytochemicals are highly exploitable and harmless, with various metabolites acting as reducing agents in the synthesis of nanoparticles, benefiting various biological science fields(11). Thus, this research work explores the antidiabetic potentials of biosynthesized MgO nanoparticles derived from *V. amygdalina* aqueous leaf extract.

## **MATERIALS AND METHODS**

### **Collection and authentication of plant leaves of *V. amygdalina***

*V. amygdalina* leaves were locally gotten from Sayedaro market at Ilaro, Ogun state, Nigeria. Authentication and identification were done at University of Lagos by a botanist with voucher number No; 8767. The leaf, renowned for its medicinal content and abundance, was chosen to test its potential as a reducing and capping agent for MgNPs, potentially benefiting humanity.

### **Preparation of leaf extract and biosynthesis of MgONPs**

The preparation of *V. amygdalina* leaves extract and synthesis of MgONPs were done according to(12). The freshly plucked leaves of *V. amygdalina* were rinsed to remove impurities like sand under running water, then washed with distilled water thrice. The washed leaves were air dried for two (2) weeks at room temperature and then ground using electrical grinding machine into powdery form. 50g of the powdery form of the leaf was measured with a weighing balance into 500ml beaker and 500ml distilled water was added. The substance was stirred continuously at 60°C for an hour, cooled to room temperature, and filtered using Whitman filter paper. A pale green color of filtrate was observed. A magnesium nitrate solution was prepared by adding 5g of magnesium nitrate in 100ml distilled water(13). 30 ml *V. amygdalina* aqueous extract and 100ml of  $Mg(NO_3)_2$  (freshly prepared) were put in a 500ml beaker and stirred for 2 hours at 80°C with a magnetic stirrer. The addition of Magnesium nitrate solution led to a significant change in color from pale green to brown, confirming the formation of MgO nanoparticles. The solution underwent centrifugation at 4000rpm/min for 4 minutes, washed with ethanol multiple times to remove impurities, and then air dried overnight.

## **Invitro Anti-diabetic Assays**

### **Determination of $\alpha$ -glucosidase enzyme inhibition**

The study involved the preparation and separation of  $\alpha$ -glucosidase from male wistar rats' small intestines. The mucosal tissue was excised, homogenized in PBS, and then dialyzed overnight. Concentrated  $\alpha$ -glucosidase from the animals was used to investigate inhibition by *V. amygdalina* leaves. The concentrated enzyme's protein content was estimated by Lowry procedures. This study examined the impact of MgONPs-*V. amygdalina* extract on rats' intestinal  $\alpha$ -glucosidase using Nagmoti and Juvekar's method. Different concentrations of the extract were incubated with the enzyme and its activity was determined by glucose oxidase method. The IC<sub>50</sub> value was used to express the enzyme inhibition data.

### **Determination of $\alpha$ -amylase enzyme inhibition**

The investigation of  $\alpha$ -amylase activity was carried out using a chromogenic method, involving mixing *V. amygdalina* extract with distilled water and soluble potato starch in a pH 6.9 phosphate buffer. 600 $\mu$ L solution of enzyme was poured into test tubes containing 300  $\mu$ L DNSA color reagent. Then, the test tubes were put in a hot water bath for 15 minutes. The reaction mixture was made watery with distilled water, and absorbance estimated. Test incubations were made for different MgONPs-*V. amygdalina* concentrations, with blank and control incubations representing 100% enzyme activity. The tests were conducted in triplicate, and the net absorbance (A) as result of generated maltose was estimated using:

$$A_{540\text{nm}} \text{MgONPs-}V. \text{ amygdalina} = A_{540\text{nm}} \text{Test} - A_{540\text{nm}} \text{Blank}.$$

The percentage of maltose derived was estimated using the maltose standard calibration curve, and the level of inhibition was calculated via this formula: % inhibition = 100 - % reaction.

### **Statistical analysis**

The data is presented as means  $\pm$  standard deviations (SD) where n= 3.

## **RESULT & DISCUSSION**

### **PRELIMINARY PHYTOCHEMICAL SCREENING**

**TABLE 1:** The Qualitative phytochemical analysis of *V. amygdalina* aqueous leaf extract

| PHYTOCHEMICALS |   |
|----------------|---|
| Saponins       | + |
| Tannins        | + |
| Phenolics      | + |
| Flavonoids     | + |
| Steroids       | + |
| Terpenoids     | + |
| Phlobatanin    | - |
| Glycosides     | + |
| Alkaloids      | + |

Key: + means test substance present, - means test substance absent

**TABLE 2:** The Qualitative phytochemical analysis of MgONPs-*V. amygdalina* aqueous leaf extract

| PHYTOCHEMICALS |   |
|----------------|---|
| Saponins       | + |
| Tannins        | + |
| Phenolics      | + |
| Flavonoids     | + |
| Steroids       | + |
| Terpenoids     | + |
| Phlobatanin    | - |
| Glycosides     | + |
| Alkaloids      | + |

Key: + means test substance present, - means test substance absent

**TABLE 3:** Quantitative Phytochemical Analysis of *V. amygdalina* aqueous leaf extract

| PHYTOCHEMICALS | CONCENTRATION (mg/100g) |
|----------------|-------------------------|
| Phenols        | 48.96±0.09              |
| Flavonoids     | 46.64±3.54              |
| Steroids       | 38.99± 1.69             |
| Tannins        | 47.26±0.09              |
| Alkaloids      | 47.14±3.42              |

Key: values are expressed in mean ± standard error.

**TABLE 4:** Quantitative Phytochemical Analysis of MgONPs-*V. amygdalina* aqueous leaf extract

| PHYTOCHEMICALS | CONCENTRATION (mg/100g) |
|----------------|-------------------------|
| Phenols        | 44.60±0.48              |
| Flavonoids     | 26.88±2.63              |
| Steroids       | 24.03±0.25              |
| Tannins        | 44.60± 0.48             |
| Alkaloids      | 26.36±0.48              |

Key: values are expressed in mean ± standard error.

## CHARACTERIZATION

### FTIR SPECTROSCOPY




Fig: 1: FTIR Spectrum data of MgONPs-*Vernonia amygdalina* aqueous leaf extract

### X-RAY DIFFRACTION ANALYSIS




Fig 2: XRD Spectrum Pattern of MgONPs-*Vernonia amygdalina* leaf aqueous extract

### SCANNING ELECTRON MICROSCOPY




Fig 3: SEM Micrographs of MgONPs-*V. amygdalina* aqueous leaf extract

**ANTIDIABETIC ACTIVITY OF MgONPs-*V. amygdalina* AQUEOUS LEAF EXTRACT**

**TABLE 5:** Effect of MgONPs-*V. amygdalina* aqueous leaf extract on  $\alpha$ -amylase

| Concentration ( $\mu\text{g/ml}$ ) | MgONPs- <i>V. amygdalina</i> leaf extract(% Inhibition) | Acarbose (% Inhibition) |
|------------------------------------|---|-------------------------|
| 20 $\mu\text{g/ml}$                | 34.54 $\pm$ 0.095                                       | 51.82 $\pm$ 0.365       |
| 40 $\mu\text{g/ml}$                | 38.45 $\pm$ 0.465                                       | 64.45 $\pm$ 0.410       |
| 60 $\mu\text{g/ml}$                | 41.40 $\pm$ 0.210                                       | 74.15 $\pm$ 0.350       |
| 80 $\mu\text{g/ml}$                | 59.75 $\pm$ 0.100                                       | 81.08 $\pm$ 0.120       |
| 100 $\mu\text{g/ml}$               | 72.56 $\pm$ 0.640                                       | 88.07 $\pm$ 0.175       |
| IC <sub>50</sub>                   | 55.05   | 20.03                   |

Values are represented as mean  $\pm$  S.D (in duplicate).  $P < 0.05$  considered as IC<sub>50</sub> significant when compared to the standard drug (Acarbose).

**TABLE 6:** Effect of MgONPs-*V. amygdalina* aqueous leaf extract on  $\alpha$ -glucosidase

| Concentration ( $\mu\text{g/ml}$ ) | MgONPs- <i>V. amygdalina</i> leaf extract(% Inhibition) | Acarbose (% Inhibition) |
|------------------------------------|---|-------------------------|
| 20 $\mu\text{g/ml}$                | 21.82 $\pm$ 0.29  | 47.42 $\pm$ 0.037       |
| 40 $\mu\text{g/ml}$                | 29.65 $\pm$ 0.30  | 52.72 $\pm$ 0.018       |
| 60 $\mu\text{g/ml}$                | 43.25 $\pm$ 1.05  | 59.99 $\pm$ 0.320       |
| 80 $\mu\text{g/ml}$                | 56.10 $\pm$ 0.65  | 68.65 $\pm$ 0.430       |
| 100 $\mu\text{g/ml}$               | 67.68 $\pm$ 0.75  | 84.09 $\pm$ 0.530       |
| IC <sub>50</sub>                   | 66.43   | 29.57                   |

Values are represented as mean  $\pm$  S.D (in duplicate).  $P < 0.05$  considered as IC<sub>50</sub> significant when compared to the standard drug (Acarbose).

Diabetes mellitus, chronic endocrine ailment affecting carbohydrate metabolism, indicated by hyperglycemia due to insufficient insulin production or cell response(14). The therapeutic

approach to diabetes involves reducing postprandial hyperglycemia.(15).This can be attained by blocking enzyme activities of  $\alpha$ -amylase and  $\alpha$ -glucosidase that hydrolyze carbohydrates.(16). The aqueous extract of the leaves of MgONPs-*V. amygdalina* can be the basis for herbal medicine to efficiently treat various diseases that affect humans such as diabetics. The phytochemical screenings revealed saponins, glycosides, terpenoids, phenols, flavonoids, steroids, tannins and alkaloids were present except phlobatanin that was absent in both crude and MgONPs synthesized extracts, however, both extracts are abundantly rich in phenols, flavonoids, steroids, tannins and alkaloids. Therefore, the phytochemicals present in this plant might be responsible for the reported anti-diabetic activities. It was also revealed from the result that values of the quantitative phytochemical constituent of the biosynthesized MgO nanoparticles extract are reduced compared to the values of the crude extract especially flavonoids and alkaloids, this can confirm that part of the phytochemical constituents contributed to the biosynthesis of MgONPs from *V. amygdalina* which are in accordance with(17).

FTIR is a technique that uses interference and absorption to study molecules' vibrations after absorption of precise infrared radiation(18). FTIR analysis identified biomolecules that can be utilized for the reduction and capping of MgONPs(19). The FTIR responses for the biosynthesized MgONPs-*V. amygdalina* aqueous extract are depicted in Figure 1. The FTIR spectra revealed the O-H stretching of intermolecular bonded alcohol at 3436 $\text{cm}^{-1}$ , the presence of C=O at 2928 $\text{cm}^{-1}$  and 2861 $\text{cm}^{-1}$ , and the stretching of ester at 1743 $\text{cm}^{-1}$ . The FTIR spectrum of *V. amygdalina* leaf extract reveals C=C stretching at 1644 $\text{cm}^{-1}$ , methylene C-H bending, -H alcohol bending, and C-O stretching at 1462  $\text{cm}^{-1}$ , 1376  $\text{cm}^{-1}$  and 1212  $\text{cm}^{-1}$ , with prominent peaks in the wave number range of 3436.69  $\text{cm}^{-1}$  to 2861.80  $\text{cm}^{-1}$ .

X-ray diffractometer was used to identify the crystallographic structure of the biosynthesized MgONPs material. The XRD pattern of synthesized MgONPs, as shown in Fig. 2, confirms the crystalline cubic structure of MgONPs through the sharp peaks observed. The peak at  $2\theta$  values of 18.3°, 19.34°, 37.77°, 58.88°, and 59.97° indicated the hexagonal shape of MgO-NPs (JCPDS)01- 073-2966). The average crystallite size of synthesized MgONPs was determined using the Scherrer formula  $D = k\lambda/\beta\cos\theta$ (20).  $D$  was calculated with values = 93°, 28°, 14°, 106°, 84° and 72°nm at  $2\theta$  peaks, therefore,  $D = 66\text{nm}$ .

SEM was used to analyze the shape of the biosynthesized MgONPs.(21)reported that the structure of biosynthesized MgO nanoparticles leave aqueous extract are in the form of cluster. In Fig.3, at 500x magnification, the particles appear clustered and some of the individual crystals are clearly seen but at higher magnification of 4000x, the hexagonal shapes of the nanoparticles are evident and separated.

$\alpha$ -glucosidase and  $\alpha$ -amylase are crucial enzymes for the breakdown of carbohydrates, with amylase breaking down long-chain carbohydrates and  $\alpha$ -glucosidase breaking down starch and disaccharides into glucose(15). Thus, hinderance of  $\alpha$ -amylase and  $\alpha$ -glucosidase activities can decrease postprandial hyperglycemia and decrease the likelihood of developing diabetes(22).

The study investigated the inhibitory action of biosynthesized MgO nanoparticles from *V. amygdalina* leaves extract and Acarbose (standard drug) that reduces carbohydrates digestion by blocking the action of pancreatic amylase(20). Table 5 shows the inhibition of  $\alpha$ -Amylase by MgONPs-*V. amygdalina* aqueous leaf extract and acarbose. The alpha amylase enzyme was

observed to be significantly inhibited at different concentrations of 20, 40, 60, 80, 100µg/ml of MgO nanoparticles *V. amygdalina* and the % inhibition were found to be 34.54,38.45,41.40,59.75, and 72.56% respectively with IC<sub>50</sub> of 55.05. Table 5 shows that the biosynthesized MgONPs- *V. amygdalina* aqueous leaf extract showed that at 100µg/ml high percentage inhibition of 72.56±0.640. Table 6 revealed that alpha glucosidase enzyme was found to be significantly blocked at different concentrations of 20, 40, 60, 80 and 100 µg/ml of MgO nanoparticles *V. amygdalina* and the percentage inhibition were found to be 21.82,29.65,43.25,56.10 and 67.68% respectively with IC<sub>50</sub> of 66.43. Table 6 showed that the biosynthesized MgONPs-*V. amygdalina* aqueous leaf extract of showed that at a concentration of 100µg/ml, a high % inhibition of 61.33±0.742% was observed. However, the blockage activities of biosynthesized MgONPs-*V. amygdalina* aqueous extract on α- glucosidase is higher than the inhibitory activity on α-amylase and this is consistence with a report by,(23).The result of this research indicates that MgONPs-*V. amygdalina* aqueous leaf extract exhibits good anti-diabetic activity and was able to decrease the activities of carbohydrate enzymes.

## CONCLUSION

This study supports the application of MgONPs-*V. amygdalina* aqueous leaf extract in the treatment of diabetes mellitus. This project recommends that MgO nanoparticles should be synthesized from other parts of the plant and their phytochemical constituents and antidiabetic activities be analyzed for further investigation.

## REFERENCES

1. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999

Sep;22(9):1462–70.

2. Keter LK, Mutiso PC. Ethnobotanical studies of medicinal plants used by Traditional Health Practitioners in the management of diabetes in Lower Eastern Province, Kenya. *J Ethnopharmacol.* 2012 Jan;139(1):74–80.
3. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pac J Trop Biomed.* 2012 Apr;2(4):320–30.
4. Shukia R, Sharma SB, Puri D, Prabhu KM, Murthy PS. Medicinal plants for treatment of diabetes mellitus. *Indian J Clin Biochem.* 2000 Aug;15(Suppl 1):169–77.
5. Farombi EO, Owoeye O. Antioxidative and chemopreventive properties of *Vernonia amygdalina* and *Garcinia biflavonoid*. *Int J Environ Res Public Health.* 2011 Jun;8(6):2533–55.
6. Kadiri O, Olawoye B. *Vernonia amygdalina*: An Underutilized Vegetable with Nutraceutical Potentials – A Review. *Turkish J Agric - Food Sci Technol [Internet].* 2016;4(9):763–768. Available from: <http://www.agrifoodscience.com/index.php/TURJAF/article/view/570>
7. Graf C, Vossen DLJ, Imhof A, van Blaaderen A. A General Method To Coat Colloidal Particles with Silica. *Langmuir [Internet].* 2003 Aug 1;19(17):6693–700. Available from: <https://doi.org/10.1021/la0347859>
8. Ghosh Chaudhuri R, Paria S. Core/Shell Nanoparticles: Classes, Properties, Synthesis Mechanisms, Characterization, and Applications. *Chem Rev [Internet].* 2012 Apr 11;112(4):2373–433. Available from: <https://doi.org/10.1021/cr100449n>
9. Pathania D, Kumar S, Thakur P, Chaudhary V, Kaushik A, Varma RS, et al. Essential oil-mediated biocompatible magnesium nanoparticles with enhanced antibacterial, antifungal, and photocatalytic efficacies. *Sci Rep.* 2022 Jul;12(1):11431.
10. Afuye OO, Olasunkanmi AA. Green synthesis of MgO Nanoparticles Using *Anona Muricata* Leaf Aqueous Extract and its Antidiabetic Activity. 2022;3(2):59–67.
11. Jeevanandam J, Chan YS, Danquah MK. Biosynthesis and characterization of MgO nanoparticles from plant extracts via induced molecular nucleation. *New J Chem [Internet].* 2017;41(7):2800–14. Available from: <http://dx.doi.org/10.1039/C6NJ03176E>
12. Vergheese M, Vishal Sk, Mary Vergheese C. Green synthesis of magnesium oxide nanoparticles using *Trigonella foenum-graecum* leaf extract and its antibacterial activity. ~ 1193 ~ *J Pharmacogn Phytochem.* 2018;7(3):1193–200.
13. Munjal S, Singh A, Kumar V. Synthesis and Characterization of MgO Nanoparticles by Orange Fruit Waste through Green Method. *Int J Adv Res Chem Sci.* 2017;4(9):36–42.
14. Edem, D.O, Edagha I, Ette BB, Agwuigwo PE. Effects of *Tapinanthus Globiferus* Leaf Extract on Blood Glucose and Pancreatic Histology in Alloxanized and Normoglycemic Rats. *Arch Diabetes Endocr Syst.* 2020 Jan 1;3:34–43.

15. Mohammed SA, Yaqub AG, Sanda KA, Nicholas AO, Arastus W, Muhammad M, et al. Review on diabetes, synthetic drugs and glycemic effects of medicinal plants. *Sect Title Pharmacol.* 2013;7(36):2628–37.
16. Dirir AM, Daou M, Yousef AF, Yousef LF. A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes. *Phytochem Rev.* 2022;21(4):1049–79.
17. Badmus JA, Oyemomi SA, Adedosu OT, Yekeen TA, Azeez MA, Adebayo EA, et al. Photo-assisted bio-fabrication of silver nanoparticles using *Annona muricata* leaf extract: exploring the antioxidant, anti-diabetic, antimicrobial, and cytotoxic activities. *Heliyon.* 2020 Nov;6(11):e05413.
18. Ajay Singh, Naveen Chandra Joshi MR. Magnesium oxide Nanoparticles (MgONPs): Green Synthesis, Characterizations and Antimicrobial activity. *Res J Pharm Technol.* 2019;12(10):4644–6.
19. Prasanth R, Dinesh Kumar S, Jayalakshmi A, Singaravelu G, Govindaraju K, Ganesh Kumar V. Green synthesis of magnesium oxide nanoparticles and their antibacterial activity. *Indian J Geo-Marine Sci.* 2019;48(8):1210–5.
20. Athithan AS, Sundari JJ, Renuga D. *Annona muricata* fruit mediated biosynthesis, physicochemical characterization of magnetite (Fe<sub>3</sub>O<sub>4</sub>) nanoparticles and assessment of its in vitro antidiabetic activity. *Rasayan J Chem.* 2020 Jan 1;13:1759–66.
21. Suresh J, Pradheesh G, Alexramani V, Mahalingam S, Hong SI. Green synthesis and characterization of hexagonal shaped MgO nanoparticles using insulin plant (*Costus pictus* D. Don) leaf extract and its antimicrobial as well as anticancer activity. *Adv Powder Technol.* 2018 Apr 1;29.
22. Heo S-J, Hwang J-Y, Choi J-I, Han J-S, Kim H-J, Jeon Y-J. Diphenylpicrylhydrazyl isolated from *Ishige okamurae*, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. *Eur J Pharmacol.* 2009 Aug;615(1–3):252–6.
23. Nurdin S, Sukohar A, Ramadani OA. Antiglucosidase and Antioxidant Activities of Ginger, Cinnamon, Turmeric and Their Combination. *Int J Pharm Pharm Res.* 2017;10(1):296–306.